Search
Back 

2018 Announcements

2018 Announcements

December 18, 2018

Join the Head and Neck Cancer Alliance in Celebrating the 2019 Oral, Head and Neck Cancer Awareness Week®, April 7-14
Head and Neck Cancer Alliance (HNCA) is hosting its Annual Oral, Head and Neck Cancer Awareness Week®, OHANCAW®, April 7-14, 2019 and looks to another record-setting year. If you have not already done so, please be sure to register your screening site today! Read more

December 17, 2018

Project Team Member Application – Hu5F9-G4 

Applicants, please submit the form to the NRG protocol development office by COB Friday, January 4, 2019. NRG Oncology will submit the application to CTEP by the deadline of January 11, 2019.

December 17, 2018
Winter holiday closure information for Operations offices, SDMC offices, and McKesson's Clinical Research Services. Read more
Winter holiday closure information for Biospecimen Banks and Serum Bank. Read more

December 13, 2018

NCTN and NCORP CIRB Requirement Policy: Implementation Date Effective March 1, 2019

NCI’s National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP) are implementing new requirements for membership in and use of the NCI Central IRB (CIRB). This policy is necessary to bring the NCTN and NCORP programs into compliance with the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research (NOT-OD-16-094). This policy applies to all United States sites enrolling patients in NCTN and NCORP studies and all Groups and Research Bases funded through the NCTN and NCORP programs. As of March 1, 2019, all sites must be members of the NCI CIRB to enroll new patients on any NCTN or NCORP trials. On this date, sites that are not CIRB members will be put in a “suspended” status on the NCTN and NCORP membership rosters and will not be able to enroll new patients to NCTN and NCORP trials. Most NRG Oncology sites are already members of the NCI CIRB but if you are not sure please contact your local IRB. Read more

November 12, 2018
Thanksgiving closure information for Operations offices, SDMC offices, and McKesson's Clinical Research Services. Read more
Thanksgiving closure information for Biospecimen Banks and Serum Bank. Read more

November 5, 2018
Veteran's Day Closure information for Philadelphia East Operations, Buffalo SDMC, and the Biospecimen Bank in San Francisco. Read more

September 13, 2018

Project Team Member Application – DS-8201a

Applicants, please submit the form to the NRG protocol development office by COB Wednesday, September 26, 2018. NRG Oncology will submit the application to CTEP by the deadline of October 3, 2018.


August 27, 2018
Labor Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson's Clinical Research Services. Read more

August 23, 2018

Matthew F. Hudson, PhD, MPH, NRG Oncology Cancer Care Delivery Research (CCDR) Vice Chair, has been appointed by the PatientCentered Outcomes Research Institute (PCORI) as a member of its Advisory Panel on Patient Engagement. Read more

July 19, 2018

The Digital Health and Personal Connected Health Minisymposium was held at the NRG Oncology Seminannual Meeting on July 12th. This session reviewed the ins-and-outs of digital health and the technology that is currently being used to improve the way we deliver cancer care.  The recording of this session is now available here.

June 25, 2018

4th of July closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson's Clinical Research Services. Read more

June 25, 2018

NRG Oncology’s GOG-0218 Trial Leads to FDA Approval of Chemotherapy with Bevacizumab for Women with Ovarian Cancer Following Initial Surgery

Read more

June 18, 2018

An Important Word from Quality Assurance About Protocol Amendments
In order to avoid problems at audit and at the time of patient enrollments,   Amendments are announced in the weekly (typically Monday) broadcast under the heading, Protocol Activity, or sometimes, they are announced during the week in a separate broadcast.  Regardless, the location/website where the amendment is posted is included in the announcement. We understand some staff have problems receiving the e-mail broadcasts; so please spread the word that broadcasts are posted to the NRG Oncology website under the News tab and can be monitored from there.

May 21, 2018

Memorial Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson. Read more

May 7, 2018
Project Team Member Application – Rogaratinib

Applicants, please submit the form to the NRG protocol development office by COB Friday, May 18, 2018. NRG Oncology will submit the application to CTEP by the deadline of May 25, 2018.


April 4, 2018

Dr. Chakravarti Selected to Serve on NCI Advisory Board of Scientific Counselors

AC

entific Counselors. In his new role, Dr. Chakravarti will be chairing the review of the NCI Radiation Oncology Program and of the NCI Neuro-Oncology Program in future years.

Dr. Chakravarti’s experience includes research regarding novel biomarkers and uncovering key molecular and genetic mechanisms of treatment resistance in cancer. His team was among the first to report that the dysregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas. 

March 30, 2018

Dr. Felix Feng Selected as the New NRG Oncology Genitourinary Cancer Committee Chair 

Felix Feng 7

N

Read more

March 23, 2018
Drs. Bernard Fisher and Norman Wolmark receive Society of Surgical Oncology's 2018 Charles M. Balch, MD Distinguished Service Award. Read more

March 12, 2018

Project Team Member Application – Radium-223

Applicants, please submit the form to the NRG protocol development office by COB Thursday, March 22, 2018. NRG Oncology will submit the application to CTEP by the deadline of March 29, 2018.


March 7, 2018

Bruner

NRG Oncology NCORP PI, Dr. Bruner, Appointed as NCI Global Health 
Working Group Co-Chair

Read more

February 19, 2018

NRG Oncology NCORP Pilot Projects
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities
that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding are:

  •  Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer 
  •  Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management  themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
  •  Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
  •  Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of  minorities and underserved populations in CPC studies
  •  Integral to these priorities, are the establishment of biospecimen repositories for molecular studies. 

For full details read more

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Care Delivery Research priorities that will provide data that will directly lead to future CCDR concepts.  As put forward in our core grant, CCDR priorities for funding are:

  • Implementation of guideline-based care
  • Patient-reported outcomes (PROs) 
  • Decision-making tools 
  • Patient navigation 
  • Cardiotoxicity 
  • Survivorship and surveillance

For full details read more

February 14, 2018

NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research  Committee Co-Chair

HudsonWeb

NRG Oncology recently appointed Matthew F. Hudson, PhD, MPH as Co-Chair for the organization’s Cancer Care Delivery Research (CCDR) Committee. He joins the present Co-Chair Debra Ritzwoller in the leadership of this committee. Drs. Hudson and Ritzwoller each represent a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) institution. Participating NCORP community sites, like the ones Drs. Hudson and Ritzwoller represent, make cancer research available to larger and more diverse patient populations. Dr. Hudson’s addition to the leadership team may enhance NRG Oncology’s capacity to evolve community-informed research protocols. Read more



February 13, 2018

Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair

Aghajanian_2017_opt636541261220150055


Read more


February 1, 2018

NRG Oncology Appoints Kati Stoermer for New Executive Director Role 

Stoermer636530970992044892

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more

NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 
NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank. Read more. 

Copyright 2019 by NRG Oncology